ReviewLife (Basel, Switzerland)2023
Novel Biomarkers and Their Role in the Diagnosis and Prognosis of Acute Coronary Syndrome.
Review in Life (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Atherogenic index of plasma and the clinical outcome of patients with acute coronary syndrome: a meta-analysis.Annals of medicine · 2025Pooled it
- The Role of Oxidative Stress and Inflammatory Parameters in Heart Failure.Medicina (Kaunas, Lithuania) · 2024Pooled it
- Redox Imbalance and Coronary Complexity Linking Oxidative Stress Biomarkers to SYNTAX II Score in Acute Coronary Syndrome.Biomedicines · 2026Article
- Carfilzomib Induces Cardiotoxicity by Blocking Autophagic Flux Through the cGAS-STING Signaling Pathway.Biomolecules · 2026Article
- Review
- miR-330-3p promotes acute coronary syndrome progression via targeting RGS5.Journal of cardiothoracic surgery · 2026Article
- Analysis of independent prognostic factors for the occurrence and severity of heart failure after chemotherapy in patients with small cell lung cancer.Experimental and therapeutic medicine · 2026Article
- Local to Systemic Inflammation-From Generation to Prognosis in Acute Coronary Syndrome.Biomedicines · 2026Review
- Differential Diagnosis between Sintilimab-related Autoimmune Myocarditis and Acute Myocardial Infarction.Biological procedures online · 2026Review
- Cumulative Serum Endothelin-1 and Endothelin-3 Level Predicts 1-year Adverse Cardiac Events after ST-Elevation Acute Myocardial Infarction.The International journal of angiology : official publication of the International College of Angiology, Inc · 2026Article
- PAPP-A Protein Diagnostic and Prognostic Significance in Acute Coronary Syndromes Without Persistent ST-T-Segment Elevation.Journal of clinical medicine · 2026Article
- Serum endocan levels in non-ST segment elevation myocardial infarction patients.Frontiers in cardiovascular medicine · 2026Article
- ECG-Guided Antiarrhythmic Therapy in Acute Coronary Syndrome: A Multidimensional Assessment of Biomarkers, Cardiac Function, and Quality of Life.Therapeutics and clinical risk management · 2026Article
- Sex-based differences in biomarker trajectories in acute coronary syndrome patients from the BIOMArCS study.Scientific reports · 2025Article
- Uric acid as a potential biomarker for cardiomyopathy in dystrophinopathy.Annals of medicine · 2025Article
- Prognostic value of elabela peptide on predicting major adverse cardiac events of NSTEMI patients in emergency department.Irish journal of medical science · 2025Article
- Dysregulation of Serum miR-212-3p Serves as a Biomarker to Predict Disease Onset and Short-Term Prognosis in Acute Coronary Syndrome Patients.Anatolian journal of cardiology · 2025Article
- Interpretable Prediction of Myocardial Infarction Using Explainable Boosting Machines: A Biomarker-Based Machine Learning Approach.Diagnostics (Basel, Switzerland) · 2025Article
- High-Sensitivity Troponins and Homocysteine: Combined Biomarkers for Better Prediction of Cardiovascular Events.International journal of molecular sciences · 2025Review
- Introducing Two Novel Indices for Evaluating Coronary Artery Stenosis: Athero-Inflammatory Index and Athero-Inflammatory Glucose Index.Journal of clinical laboratory analysis · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The burden of cardiovascular diseases and the critical role of acute coronary syndrome (ACS) in their progression underscore the need for effective diagnostic and prognostic tools. Biomarkers have emerged as crucial instruments for ACS diagnosis, risk stratification, and prognosis assessment. Among these, high-sensitivity troponin (hs-cTn) has revolutionized ACS diagnosis due to its superior sensitivity and negative predictive value. However, challenges regarding specificity, standardization, and interpretation persist. Beyond troponins, various biomarkers reflecting myocardial injury, neurohormonal activation, inflammation, thrombosis, and other pathways are being explored to refine ACS management. This review article comprehensively explores the landscape of clinically used biomarkers intricately involved in the pathophysiology, diagnosis, and prognosis of ACS (i.e., troponins, creatine kinase MB (CK-MB), B-type natriuretic peptides (BNP), copeptin, C-reactive protein (CRP), interleukin-6 (IL-6), d-dimers, fibrinogen), especially focusing on the prognostic role of natriuretic peptides and of inflammatory indices. Research data on novel biomarkers (i.e., endocan, galectin, soluble suppression of tumorigenicity (sST2), microRNAs (miRNAs), soluble oxidized low-density lipoprotein receptor-1 (sLOX-1), F2 isoprostanes, and growth differentiation factor 15 (GDF-15)) are further analyzed, aiming to shed light on the multiplicity of pathophysiologic mechanisms implicated in the evolution of ACS. By elucidating the complex interplay of these biomarkers in ACS pathophysiology, diagnosis, and outcomes, this review aims to enhance our understanding of the evolving trajectory and advancements in ACS management. However, further research is necessary to establish the clinical utility and integration of these biomarkers into routine practice to improve patient outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.